Clinical trials: Type 2 Diabetes (T2D)
Diabetes Mellitus, Type 2
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below…
- Trial name
- GALAPAGOS (NCT01121835)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, PREMIXED INSULIN
- Where
- 96 sites in Austria, Brazil and 14 more
- Volunteers
- 934 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01481116
- Testing
- TAK-875, Glimepiride
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,454 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)
The purpose of this study is to determine if the addition of ezetimibe 10 mg daily to ongoing 20 mg simvastatin daily will reduce LDL Cholesterol to a greater extent than increasing the dose of simvastatin to 40 mg daily in Type…
- Trial name
- NCT00551876
- Testing
- MK0653, ezetimibe / Duration of Treatment: 30 Weeks, Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks
- Volunteers
- 214 people
- Sponsor
- Organon and Co
Type II Diabetes Mellitus
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
This is a multicenter randomized, double-blind, placebo- and active-controlled (liraglutide; Victoza®), parallel-group, clinical trial of MK-8521 in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT02492763
- Testing
- MK-8521, Liraglutide, Metformin
- Volunteers
- 176 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin
This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.
- Trial name
- 3283K1-1008-US (NCT00970593)
- Testing
- OAP-189
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
TOFO Insulin Combination Trial
Primary Objectives: To assess the effects of tofogliflozin on glycemic control in comparison to placebo as an add-on treatment to insulin treatment in terms of glycated hemoglobin (HbA1c) reduction over a period of 16 weeks in…
- Trial name
- NCT02201004
- Testing
- TOFOGLIFLOZIN CSG452, insulin
- Where
- 30 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
This study will investigate efficacy and safety of vildagliptin in patients with low baseline levels starting at an HbA1C level of 6.5% to support convenient early intervention with combination therapies.
- Trial name
- NCT00494884
- Testing
- vildagliptin
- Where
- Germany
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
Warfarin is a commonly used drug to prevent the blood from clotting. The purpose of this study is to determine if dulaglutide (LY2189265) affects how warfarin works.
- Trial name
- NCT01432938
- Testing
- dulaglutide, Warfarin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Obesity
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes.
- Trial name
- NCT05514535
- Testing
- Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
- Where
- 239 sites in United States, Czechia and 10 more
- Volunteers
- 573 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Trial name
- NCT02964104
- Testing
- Insulin icodec, insulin degludec
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)
To evaluate the effect of treatment with sitagliptin compared to placebo in elderly patients with type 2 diabetes mellitus who have poor glycemic control with diet and exercise.
- Trial name
- NCT00305604
- Testing
- sitagliptin phosphate
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Glucose Lowering
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.
- Trial name
- NCT01069926
- Testing
- AZD1656
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin
The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch.
- Trial name
- SWING (NCT00549887)
- Testing
- Analog or Human Insulin
- Where
- 27 sites in Austria, Czechia and 7 more
- Volunteers
- 2,459 people
- Sponsor
- Eli Lilly and Company
Heart Diseases, Diabetes Mellitus, Type 2
A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation…
- Trial name
- NCT00415428
- Testing
- Patient adherence to national educational guidelines.
- Volunteers
- 2,776 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
T2DM (Type 2 Diabetes Mellitus)
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination with Metformin in Patients With Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Metformin Alone.
- Trial name
- ENHANCE-M (NCT04634500)
- Testing
- Dapagliflozin
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy.
- Trial name
- NCT00525330
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- ActivX Biosciences, Inc.
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07684144
- Testing
- Maridebart Cafraglutide
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 950 people
- Sponsor
- Amgen
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB2 (NCT03252964)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Savvysherpa, Inc.
Diabetes
Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus
This will be a randomized, cross-over design. Subjects will be randomized to one of six interventions on six separate study days, 1 week apart.
- Trial name
- NCT03155867
- Testing
- Meal replacement
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Société des Produits Nestlé (SPN)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.